Mustang Bio, Inc. MBIO

MBIO Company Overview

Mustang Bio, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cell and gene therapies for cancers and rare genetic diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on engineered T-cell therapies, hematopoietic stem cell gene therapies, and ex vivo lentiviral gene therapy platforms. Mustang Bio has historically concentrated on therapies targeting hematologic malignancies, solid tumors, and inherited disorders through collaborations with academic research institutions and licensed technologies.

The company’s primary business model centers on advancing internally developed and in-licensed therapeutic candidates through clinical development, with future revenue potential tied to commercialization, strategic partnerships, licensing arrangements, and milestone-based collaborations. Mustang Bio was founded in 2015 as part of the Fortress Biotech ecosystem and became publicly traded on Nasdaq under the ticker MBIO in 2017. Over time, the company evolved from a broad cell-therapy development platform into a more selective pipeline strategy focused on programs with potentially differentiated clinical utility and orphan disease applications.